Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vascular Biogenics's current ratio for the quarter that ended in Jun. 2023 was 4.63.
Vascular Biogenics has a current ratio of 4.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Vascular Biogenics's Current Ratio or its related term are showing as below:
STU:0VB'
s Current Ratio Range Over the Past 10 Years
Min: 1.5 Med: 6.45 Max: 13.12
Current: 4.63
During the past 11 years, Vascular Biogenics's highest Current Ratio was 13.12. The lowest was 1.50. And the median was 6.45.
STU:0VB's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.88
vs STU:0VB: 4.63
Vascular Biogenics (STU:0VB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vascular Biogenics Current Ratio Related Terms
Vascular Biogenics Current Ratio Historical Data
* Premium members only.
The historical data trend for Vascular Biogenics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0VB vs MBIO, GNPX, LEXX: Current Ratio Comparison
For the Biotechnology subindustry, Vascular Biogenics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Biogenics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics (STU:0VB) has a Current Ratio of 4.63 as of Jun. 2023. This is 28% below median its historical median of 6.45. Over the past decade, Vascular Biogenics' Current Ratio has ranged from 1.50 to 13.12.
Is Vascular Biogenics' Current Ratio too high?
Vascular Biogenics' current Current Ratio of 4.63 is 28% below median its 10-year median of 6.45. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 13.12. The Biotechnology industry median Current Ratio is 3.88. Vascular Biogenics' value of 4.63 is 19.3% above this industry median. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' Current Ratio compare to MBIO and GNPX?
Vascular Biogenics' Current Ratio of 4.63 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.88. Vascular Biogenics' value of 4.63 is 19.3% above this benchmark. Historically, Vascular Biogenics' own Current Ratio has ranged from 1.50 to 13.12 over the past decade. While the company's 10-year median is 6.45 vs. the industry median of 3.88, Vascular Biogenics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vascular Biogenics's current Current Ratio of 4.63 is 19.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vascular Biogenics's current Current Ratio is 4.63, which is 28% below median its own 10-year median of 6.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current Current Ratio of 4.63. The current Current Ratio is 4.63, which is 28% below median its 10-year median of 6.45 and 19.3% above the Biotechnology industry median of 3.88. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current Current Ratio is 4.63 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0VB has been successfully added to your 
